Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 59, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijantimicag.2021.106475
Keywords
Bacteriophage therapy; CRISPR-Cas; Antimicrobial; Phage-based vector
Ask authors/readers for more resources
Multidrug-resistant bacterial infections are on the rise worldwide, posing a significant threat to human health. Phage therapy and the CRISPR-Cas system have shown promise in combating these infections.
Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials. (C) 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available